Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy  

作　　者：Wei Tan Jian Wang Pei-Mei Shi Ling-Mei Feng Jian Shi Bei-Fang Ning Zong-Li Yuan Xin Zeng Wei-Fen Xie 

机构地区：[1]Department of Gastroenterology,Changzheng Hospital,Naval Medical University,Shanghai,China [2]Department of Gastro-enterology,Shanghai East Hospital,Tongji University School of Medicine,Shanghai,China

出　　处：《Journal of Clinical and Translational Hepatology》2022年第6期1099-1106,共8页临床与转化肝病杂志（英文版）

摘　　要：Background and Aims:Rifaximin is effective in prevent-ing and treating hepatic encephalopathy(HE).This study aimed to investigate the efficacy and safety of different dosages of rifaximin in the treatment of cirrhotic patients with covert HE(CHE).Methods:In this single-center,ran-domized,controlled,open-label study,CHE was diagnosed using a combination of the psychometric HE score and the EncephalApp Stroop test.Cirrhotic patients with CHE were recruited and randomly assigned to low-dose rifaximin 800 mg/day,high-dose rifaximin(1,200 mg/day),and control groups,and were treated for 8 weeks.The sickness impact profile(SIP)scale was used to evaluate the health-relat-ed quality of life(HRQOL)of patients.Forty patients were included in the study,12 were assigned to the low-dose group,14 to the high-dose group,and 14 patients to the control group.Results:The percentage of patients with CHE reversal was significantly higher in both the low-dose(41.67%,5/12)and high-dose(57.14%,8/14)groups than in the control group(7.14%,1/14)at 8 weeks(p=0.037 and p=0.005,respectively).In addition,both doses of ri-faximin resulted in significant improvement of the total SIP score compared with the control group.There were no sig-nificant differences in the CHE reversal rate,total SIP score improvement,and incidence of adverse event between the low-dose and high-dose groups(p>0.05).Conclusions:Low-dose rifaximin reverses CHE and improves HRQOL in cirrhotic patients with comparable effects and safety to high-dose rifaximin.

关 键 词：Single-center open-label study Randomized prospective study Liver cirrhosis Covert hepatic encephalopathy RIFAXIMIN 

分 类 号：R575.3[医药卫生—消化系统]